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Aberrant hypermethylation of gene promoter regions is one of the mechanisms for inactivation of tumour suppressor genes in
many human cancers including breast carcinoma. In the current study, we aimed to assess by MSP, the methylation pattern of
two cancer-related genes involved in DNA repair: hMLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) and BRCA1
(breast cancer 1, early onset) in 78 primary breast cancers from Tunisian patients. The methylation frequencies were 24.36% for
hMLH1 and 46% for BRCA1. BRCA1 methylation correlated with age at diagnosis (P = .015) and 5-years disease free survival
(P = .016) while hMLH1 methylation was more frequent in larger tumors (P = .002) and in presence of distant metastasis
(P = .004). Furthermore, methylation of hMLH1 signiﬁcantly correlated with high level of P53 expression (P = .006) and with
overall survival (P = .015) suggesting that silencing of hMLH1 through aberrant promoter methylation could be used as a poor
prognosis indicator in breast cancer.
Copyright © 2009 Sondes Karray-Chouayekh et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
Breast cancer is the ﬁrst cause of cancer mortality among
women worldwide and the overall lifetime risk for develop-
ing invasive breast cancer is estimated to 10% [1]. In Tunisia,
breast cancer is the second most frequent cancer among
females and in the south area the incidence is of 30/100000
[2]. Tunisian breast cancer is characterized by a particular
aggressive proﬁle compared with Western countries as the
incidence is more prevalent in young (<35 years) than
older patients [3]. Breast cancer results of abnormal genetic
as well as epigenetic changes [4]. Promoter-CpG islands
hypermethylation, associated with global hypomethylation,
are common molecular defects in cancer cells [5].
CpG islands, frequently located at the 5 -end regulatory
regions of genes, are subject to epigenetic modiﬁcations
including DNA methylation and histone modiﬁcation that
are known to play an important role in regulating gene
expression [5]. In normal cells, the majority of promoter
CpG islands are protected from this epigenetic event and
thus they are unmethylated. Conversely, in cancer cells,
several promoter CpG islands are hypermethylated and form
a closed repressive chromatin conﬁguration that aﬀects the
transcription initiation of the corresponding genes [6–8].
In breast cancer, more than 40 genes have been shown
to be inactivated by methylation including those involved
in DNA repair, cell-cycle regulation, tumor suppression,
cell adhesion and cell signalling [9–12]. The identiﬁcation
of these methylated genes has signiﬁcantly contributed to
elucidate the molecular pathways which are altered in breast
carcinoma and provided potential targets for molecular
detection.
Recent studies suggested that methylation proﬁles of
cancers depend on tumor type and ethnicity [13, 14]. In
this context, the methylation status of breast cancer patients
fromWesternpopulationiswelldocumentedwhereasthatof
Tunisian breast cancer is still not well studied except a recent
work on the relationship between SV40 status and promoter2 Journal of Biomedicine and Biotechnology
Table 1: Summary of primer sequences, annealing temperature, product size and number of cycle used in MSP assay. M: methylated DNA,
U :u n m e t h y l a t e dD N A ,F :f o r w a r d ,R :R e v e r s e .
Gene Sequence (5 -3 ) Tm (◦C) Size (bp) PCR cycles
hMLH1 (U) F TTTTGATGTAGATGTTTTATTAGGGTTGT 60 114 30
R ACCACCTCATCATAACTACCCACA
hMLH1 (M) F ACGTAGACGTTTTATTAGGGTCGC 58 110 30
R CCTCATCGTAACTACCCGCG
BRCA1I (U) F GGTTAATTTAGAGTTTTGAGAGATG 60 75 30
R TCAACAAACTCACACCACACAATCA
BRCA1 (M) F GGTTAATTTAGAGTTTCGAGAGACG 60 86 30
R TCAACGAACTCACGCCGCGCAATCG
hypermethylation in patients from the central region of
Tunisia [15].
Therefore, our study was initiated with the aim to assess
the methylation proﬁle of two genes involved in DNA repair:
hMLH1 (mutL homolog 1, colon cancer, nonpolyposis type
2 (E. coli) and BRCA1 (breast cancer 1, early onset). We
next explored for associations between gene methylation
and clinicopathological features, hormone receptors, and
patients survival.
BRCA1 and hMLH1 have been shown to be methylated
in tumors leading to the downregulation of gene expression
[16–20]. The hMLH1 gene is a member of the DNA mis-
match repair system which corrects DNA base-pairing errors
in newly replicated DNA [21]. Deﬁciencies in this system
result in mutation rates 100-fold higher than those observed
in normal cells [22, 23]. Besides its involvement in DNA
repair, BRCA1 is a tumor suppressor gene located on 17q12-
21. Loss of the wild-type allele (LOH) is required for tumori-
genesis in germ line mutation carriers. Hypermethylation of
the BRCA1 promoter has been shown to be one of the mech-
anisms leading to functional inactivation of BRCA1 [24].
2.MaterialandMethods
2.1. Patients Characteristics. A total of 78 fresh-frozen pri-
mary breast cancer tissues were collected from the Anatomo-
Pathology; CHU Habib Bourguiba of Sfax in Tunisia with
Institutional Review Board approval. The age at diagnosis
ranged from 28 to 73 years, with a mean of 50.6. All
cases were graded according to the modiﬁed Scarﬀ- Bloom-
Richardson system [25]. The clinical stage of the disease was
determined according to TNM classiﬁcation of the Interna-
tional Union Against Cancer [26]. Clinical-pathological data
(age, histological grade, tumor size, lymph node status, and
distant metastasis) are summarized in Table 1.
2.2. DNA Extraction. Genomic DNA was extracted from
fresh-frozen specimens using the standard protocol with
Proteinase K in the presence of SDS at 37◦C overnight,
followed by phenol/chloroform extraction as described pre-
viously[27]. Brieﬂy tissues sections were incubated in 100μL
TE (10mM Tris-Hcl, pH 8.0, 1mM EDTA) containing 40μg
proteinase K at 55◦Cf o r4h o u r s .D N Aw a se x t r a c t e dw i t h
a mixture of phenol-chloroform-isoamyl alcohol (25 : 24 :
1) and precipitated with ethanol at −20◦C. The quantity
of DNA was checked by spectrophotometer and stored at
−20◦C for further use.
2.3. Methylation-Speciﬁc-PCR (MSP). DNA samples (1 to
2μg) were modiﬁed with sodium bisulﬁte that converts the
unmethylatedcytosinesbutnotthemethylatedonestouracil
using the Methyl Detector Kit as recommended by Active
Motif (Belgium). The bisulﬁte-treated DNA was ampliﬁed
using speciﬁc primers for methylated and unmethylated
alleles as described by Herman et al. [28]. Sequences of the
primers, annealing temperature, and product size are listed
in Table 1.
PCRwascarriedoutinatotalvolumeof25μLcontaining
2μM of each primer pair, 200μMd N T P ,1 . 5m MM g C l 2,1 X
PCR buﬀer, and 1U of Taq DNA polymerase (Fermentas).
Each PCR reaction underwent initial denaturation at 95◦C
for 10 minutes, and 35 cycles of the following proﬁle: 30
seconds at 94◦C, 30 seconds at optimal T◦ (Table 1), and 30
seconds at 72◦C followed by a ﬁnal 10 minutes extension
at 72◦C. Fully methylated DNA (Active Motif, Belgium)
and lymphocytes DNA from healthy individual were used
as positive controls for the methylated and unmethylated
reactions, respectively. Blank control without DNA was
included in each PCR assay. After ampliﬁcation, products
were electrophoresed using 2% agarose gels, stained with
ethidium bromide and visualized under UV illumination.
2.4. Immunohistochemistry. Immunostaining of Estrogen
(ER) and Progesteron (PR) receptors was performed for
all specimens, while HER/neu and p53 protein expression
was investigated in 64 and 39 specimens, respectively. Four
micrometers sections attached on silanized slides were de-
waxed in xylene, rehydrated in graded ethanol, and covered
with 10mM citrate buﬀer (pH 6). Slides were incubated
for 30 minutes with primary monoclonal antibodies against:
ER (Dako, clone 1D5, 1 : 25), PR (Dako, clone PgR636,
1 : 50), HER2/neu (Dako, clone 124, 1 : 100), and p53 (clone
DO-7, Dako Cytomation 1 : 50) followed by incubation
with biotin-labelled secondary antibodies. The streptavidin-
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Figure 1: Electrophoresis of PCR products spanning the BRCA1 and hMLH1 promoters from bisulﬁte-treated DNA in breast cancer tissues.
Each lane contains products generated from separate PCR reactions using primers speciﬁc for unmethylated (U) or methylated (M) DNA
template. Fully methylated DNA from Active Motif and Blood from healthy individual used as a positive control (C) for methylated and
unmethylated DNA (B). The lanes marked (H2O) indicates water only without the addition of DNA and (L) 100-bp ladder as molecular
weight markers (Fermentas).
as a chromogenic substrate. All slides were evaluated without
knowledge of the clinical outcome. Sections were considered
to be positive if more than 5% of tumor cells were stained.
Foreachrunofstaining,positivecontrolslideswereprepared
from breast carcinoma known to be positive for the proteins
under study. The HER2/neu and p53 immunostaining were
scored from 0 to 3 according to the criteria set by Dako.
The staining was scored as negative (0) when no membrane
stainingwasobservedforHER2/neu,andnonuclearstaining
for p53, or when staining was observed in less than 10% of
the tumor cells, weak positive (1+) if weak focal staining was
seen in more than 10% of the tumor cells, intermediate (2+),
ifweaktomoderate,completestainingwasseeninmorethan
10% of the tumor cells and strongly positive (3+) if intense
and complete staining in more than 10% of the tumor cells.
In the ﬁnal analysis, scores 0, 1, and 2 were considered as
negative, only score 3 was retained as positive in HER2/neu
overexpression cases. However, scores 0 and 1 were negative
and score 2 and 3 were considered as positive for p53.
2.5. Data Analysis and Statistics. The association between
aberrant hypermethylation and clinicopathological parame-
ters was checked by the χ2 test. All variables (age, stage, his-
tological grade, lymph node involvement, distal metastasis,
hormone receptor status, and CpG island hypermethylation)
were also subjected to multivariate analysis using Logistic
regression. Survival curves were constructed according to the
method of Kaplan Meier. For diﬀerences between curves,
the P value was calculated using the log rank test. All the
statistical analysis was performed using the software SPSS for
Windows version 13.0. P<. 05 was considered as statistically
signiﬁcant.
3. Results andDiscussion
3.1. Methylation Proﬁles of BRCA1 and hMLH1 in Tumor
Tissues. Aberrant methylation of the promoter region is
considered as one of the major mechanisms for silencing
of cancer-related genes, resulting in downregulation of gene
expression. It has been demonstrated that CpG islands
hypermethylation is implicated in the loss of expression of
critical tumor suppressor and growth regulatory genes lead-
ing to cancer development and progression [5–8]. Analysis
of promoter methylation of BRCA1 and hMLH1 was carried
out in 78 and 74 invasive primary breast tissues, respectively.
Figure 1 shows representative examples of MSP results. The
frequency of promoter hypermethylation was 44.8% (35 out
of 78) for BRCA1 and 24.3% (17 out of 74) for hMLH1.
Among the 78 malignant tissues, more than a half exhibited
at least one methylated gene (62%). In other hand, for some
samples,weobservedboththemethylatedandunmethylated
alleles, this can be probably explained by the presence of
inﬁltratinglymphocytesand/ornonmalignantepithelialcells
in the primary tumors.
When we reviewed the literature, the methylation fre-
quency ranged from 8 to 43.5% for hMLH1 and from 11 to
60% for BRCA1 [20, 29–32]. In our series, the frequencies
of BRCA1 and hMLH1 methylation were in the middle of the
range of previous studies. These diﬀerences may be explained
by several factors: (i) unmethylated DNA from the normal
cells inﬁltrating the tumor might attenuate the methylation
levels and (ii) number of CpG within the region of interest.
Toavoidmisinterpretationofourresults,weincludedineach
assay, both methylated and unmethylated DNA as controls.
On the other hand, several investigations have attempted
to identify the racial/ethnic diﬀerences in promoter hyper-
methylation. Bae et al. evaluated promoter methylation
status in American and Korean breast cancers patients and
they found no signiﬁcant interethnic diﬀerences [13]. More
recently, it was reported that there are many similarities
of promoter hypermethylation proﬁles between Korean and
Caucasian women, but also dissimilarities that characterize
tumors of one ethnicity from the other [14].
3.2. Relationship between Methylation Status and Clinico-
pathological Characteristics. The relationship between pro-
moter hypermethylation of hMLH1 and BRCA1 genes and
clinicopathological parameters was summarized in Table 2.
Statistical analysis showed that BRCA1 hypermethylation
was associated with age at diagnosis (P = .015, Table 2)
since 72% of patients ≤45 years displayed the methylated
pattern. This observation suggests that loss of BRCA1
expression through aberrant promoter methylation occurred
more frequently in young women with breast carcinoma4 Journal of Biomedicine and Biotechnology
Table 2: Association between gene promoter methylation and clinicopathological features ER and p53 expression in breast cancer.
BRCA1 hMLH1
M (%) U (%) P(b) M (%) U (%) P(b)
N 78 35 (44.8) 43 (55.1) 17 (21.7) 57 (73)
Age
≤45 30 19 (63.3) 11 (36.7) 6 (21.4) 22 (78.6)
>45 48 16 (33.3) 32 (66.7) 11 (23.9) 35 (76.1)
.01 .8
Tumor size
T ≤ 30mm 38 18 (47.4) 20 (52.6) 3 (8.1) 34 (91.9)
T > 30mm 40 17 (42.5) 23 (57.5) 14 (37.8) 23 (62.2)
.66 .002
(a)Metastasis
No 37 18 (48.6) 19 (51.4) 1 (2.8) 35 (97.2)
Yes 14 8 (37.1) 6 (42.9) 4 (30.8) 9 (69.2)
.58 .004
(a)DFS
<5 years 22 7 (31.8) 15 (68.2) 3 (14.3) 18 (87.5)
>5 years 12 9 (75) 3 (25) 1 (8.3) 11 (91.7)
.015 .6
(a)Response to radiotherapy
Radiosensitive 37 18 (48.6) 19 (51.4) 1 (2.8) 35 (97.2)
Radioresistant 14 8 (57.1) 6 (42.9) 4 (30.8) 9 (69.2)
.58 .004
ER
Positive 19 9 (47.4) 10 (52.6) 7 (36.8) 12 (63.2)
Moderate 28 11 (39.3) 17 (60.7) 2 (7.7) 24 (92.3)
Negative 31 15 (48.4) 16 (51.6) 8 (27.6) 21 (72.4)
.75 .054
(a)P53
Positive 16 9 (56.3) 7 (43.8)
Negative 23 10 (43.5) 13 (56.5) 5 (68.8) 11 (31.3)
0 (0) 21 (100)
.44 .006
DFS: Disease Free Survival, ER: Estrogen Receptor.
(a)Data for DFS, response to radiotherapy, metastasis, and p53 status were not available for all specimens.
(b)Comparisons of DFS and P53 status was made by Fisher’s exact test and all other comparisons were by the 2 test.
which is known to have a particular more aggressive feature.
Despite age, no other association was found with patients’
characteristics and BRCA1 methylation status. Nevertheless,
by multivariate analysis, we found a signiﬁcant association of
BRCA1 promoter methylation with clinical stage, tumor size
and 5-year survival (P = .022, .037 and .017, resp., Table 3).
The most consistent associations were seen between
hMLH1 promoter hypermethylation and tumor size and
distant metastasis (P = .002 and .004, resp., Table 2). This
result leads us to suggest that hypermethylation of hMLH1
gene promoter seemed to confer advantage for tumors cells
invasion, and it may be used as a marker of advanced breast
cancer.Inthiscontext,itwasreportedthathypermethylation
of hMLH1 was signiﬁcantly associated with advanced stage
and lymphatic metastasis [19, 29]. Our ﬁnding is consistent
with those studies since a trend of association was found
Table 3: Multivariate analysis of BRCA1 methylation status and
clinical features.
Clinical features BRCA1 Methylation
PO R9 5 %CI
Age .11 0.17 0.02–1.5
TNM .218 0.173 0.01–2.81
Clinical stage .022 53.8 1.7–1640
Metastasis .891 0.8 0.03–16.6
Tumor size .037 0.05 0.004–0.84
5-y survival .017 20.7 1.7–251.5
between methylated hMLH1 proﬁle and clinical stage of
breast cancer. In fact, 14.3% of hMLH1 methylated tumors
are of stage T III, IV versus 4.8% of early stage althoughJournal of Biomedicine and Biotechnology 5
Table 4: Correlation between p53 expression level and double negative (ER−/PR−,E R −/HER2−) and triple negative (ER−/PR−/HER2−)
breast cancer.
N ER−/PR− ER−/HER2− ER−/PR−/HER2−
Yes No Yes No Yes No
P53
Positive 16 10 (62.5%) 6 (37.5%) 8 (50%) 8 (50%) 7 (43.8%) 9 (56.3%)
Negative 23 3 (13%) 20 (87%) 3 (13%) 20 (87%) 2 (8.7%) 21 (91.3%)





Figure 2: Representative result of p53 immunohistochemical
staining and hMLH1 promoter methylation. (a) Breast tumor
specimen with p53 nuclear positivity associated with both hMLH1
methylated and unmethylated DNA. (b) Breast tumor specimen
negative for p53 correlated with unmethylated hMLH1 proﬁle.
the diﬀerence was not statistically signiﬁcant (P = .276).
Furthermore, we detected a signiﬁcant correlation between
responsetotreatmentandhMLH1methylationbyunivariate
(P = .004, Table 2).
3.3. Relationship between Methylation of Individual Genes
and ER, PR, HER2/neu, and P53 Status. The ER, PR,
and HER2/neu are important prognostic biomarkers and
therapeutic targets in primary breast cancer. ER-negative
tumors appear to be more malignant, resulting in a poorer
prognosis than ER-positive tumors [33, 34]. Expression of
HER2/neu, ER, and PR proteins are considered as predictive
marker for response to hormone therapy in breast cancer.
High to moderate level of ER expression was detected in
60.3% of tumors while 39.7% of cases were ER− (Table 1).
Univariate analysis, revealed that ER status was weakly
associated with hMLH1 methylation (P = .054, Table 1).
No other signiﬁcant association between the methylation
proﬁle of hMLH1 or BRCA1 and PR, HER2/neu status
was noted in our series. In breast cancer, methylation has
already been connected to hormone regulation, but the
correlation is not clear yet. Campan et al., reviewed the
DNA methylation proﬁles of breast, endometrial, ovarian,
and proximal colon cancers but did not ﬁnd evidence
for global hormone-speciﬁc DNA methylation alterations
[35]. On the other hand, Widschwendter et al. reported
signiﬁcant diﬀerences in hormone receptor status between
clusters of DNA methylation proﬁles [36]. Recently, it
was demonstrated that epigenetic diﬀerences between ER-
positive and ER-negative breast tumors arise early in cancer
development and persist during cancer progression [37].































Figure 3: Kaplan-Meier survival curve correlating overall survival
with hMLH1 methylated and unmethylated proﬁle.
In the current study, p53 expression was assessed by
IHC in 39 specimens. Nuclear staining was seen in 41%
(16 out of 39) of cases. Figure 2 shows an example of
specimen with p53 positive (a) and negative (b) nuclear
staining. Interestingly, we found that all tumors displaying
unmethylated hMLH1 proﬁle were negative for p53 (P =
.006, Table 2, Figure 2). This observation suggests a positive
association between methylated hMLH1 and functional p53.
Furthermore, p53 expression was signiﬁcantly connected to
hormonereceptorstatus.Indeed,highlevelofp53expression
was associated with double negative (ER−/PR−, P = .001
and ER−/HER2−, P = .011, Table 4) and triple negative
(ER−/PR−/HER2−, P = .01, Table 4) tumors. Our data
was consistent with previously reported results showing
that triple negative breast cancers correlated with high p53
expression level [37]. It was well established that triple
negative breast cancer has aggressive clinical features and
reduced survival [38]. In the current work, we showed that
triple negative breast cancer correlated with 5-year survival,
(P = .002; OR = 0.083, 95%CI = 0.015–0.462) while
no statistically signiﬁcant association was found with overall
survival and triple negative tumors in our series. Recently,
Rhee et al., reported that most of the relapses in triple
negative breast cancer occur within the ﬁrst 3 years, in
contrast to tumors expressing ER, PR, and HER2/neu [37].6 Journal of Biomedicine and Biotechnology
Altogether, these ﬁndings reﬂect the aggressiveness of triple
negative breast cancer as previously reported [38].
3.4. Relationship between Methylation of hMLH1 and Overall
Survival. T h es u r v i v a lr a t ew a sa v a i l a b l ef o r3 4p a t i e n t s
and the follow-up time ranged from 3 to 119 months. The
Kaplan-Meier method was used to correlate hMLH1 and
BRCA1methylationstatuswithoverallsurvival.Asshownon
Figure 3, patients with unmethylated hMLH1 gene promoter
have a signiﬁcant prolonged survival rate compared to those
withmethylatedproﬁle(P logrank =.015).Tothebestofour
knowledge, this is the ﬁrst report about the involvement of
hMLH1hypermethylationwithpatients’outcomesuggesting
that it could be an important prognostic factor of breast
cancer. However this ﬁnding should be conﬁrmed on larger
series. In the current study, BRCA1 methylation and survival
association was of borderline signiﬁcance (P log-rank =
.065). Recently, it was reported in a large cohort of 851
patients that BRCA1 methylation was associated with breast
cancer-speciﬁc mortality [39].
4. Conclusion
In summary, we examined BRCA1 and hMLH1 promoter
methylation status and explored the relationship with clini-
copathological factors and breast cancer survival. Promoter
methylation of hMLH1 was more frequent in cancers
with distant metastasis and in larger tumors (greater than
3cm) whereas BRCA1 hypermethylation was higher in
patients under 45 years. Furthermore, aberrant methylation
of hMLH1 correlated with reduced overall survival while
BRCA1 hypermethylation associated with 5-year survival.
Our results indicate that BRCA1 and hMLH1 promoter
methylation could be an important prognostic factor of
breast cancer.
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